摘要
目的分析对鼻咽癌患者根治性放化疗后卡培他滨辅助化疗的治疗效果与安全性情况。方法选取2014年4月-2016年4月在医院肿瘤放射治疗科中选择患有鼻咽癌的患者,将其作为研究对象,其中,将接受根治性放化疗后卡培他滨辅助化疗的局部晚期(T3~4N2~3M0)鼻咽癌患者25例患者作为研究组,同时,选取25例仅接受根治性放化疗的患者作为对照组。对治疗效果及安全性进行初步比较。结果分析结果显示,在生存率方面,治疗2年后,研究组的生存率为96%,对照组的生存率为95%,研究组略高于对照组,差异有无统计学意义(P>0.05);在毒副作用方面,研究组出现的3级与4级毒副反应主要包括血小板减少、白细胞减少以及恶心呕吐,出现的概率分别为4%、16%和16%,对照组上述三种毒副作用的发生率分别为4%、12%和16%,差异无统计学意义(χ^2=0.000,1.299,0.000;P=1.000,0.393,1.000)。结论局部晚期鼻咽癌患者根治性放化疗后辅助卡培他滨化疗,患者未增加严重毒副反应,患者2年的生存率有所提高,长期疗效及不良毒副反应需要继续观察随访。
Objective To analyze the therapeutic effect and safety of capecitabine adjuvant chemotherapy after radical chemoradiotherapy in patients with nasopharyngeal carcinoma.Methods Patients with nasopharyngeal carcinoma were selected from the department of radiation oncology in hospital from April 2014 to April 2016 as subjects.Among them,capecitabine adjuvant chemotherapy after radical chemoradiotherapy will be performed.25 patients with locally advanced(T3~4N2~3M0)nasopharyngeal carcinoma were enrolled in the study group.At the same time,25 patients who underwent radical chemoradiotherapy were selected as the control group.A preliminary comparison of treatment effectiveness and safety.Results The results of the analysis showed that in the survival rate,after 2 years of treatment,the survival rate of the study group was 96%,and the survival rate of the control group was 95%.The study group was slightly higher than the control group,and the difference was statistically significant(P>0.05);In terms of side effects,the grade 3 and 4 toxic side effects in the study group mainly included thrombocytopenia,leukopenia,and nausea and vomiting.The probability of occurrence was 4%,16%,16%,respectively.The incidence rates of the above three toxic side effects were 4%,12%,16%,respectively,and the difference was not statistically significant(χ^2=0.000,1.299,0.000;P=1.000,0.393,1.000).Conclusion Patients with locally advanced nasopharyngeal carcinoma underwent radical radiotherapy and chemotherapy after adjuvant chemotherapy with capecitabine.The patients did not increase severe toxic and side effects.The 2-year survival rate of patients improved.Long-term efficacy and adverse side effects required continued observation.
作者
陈贵平
CHEN Guiping(Department of Radiotherapy,Zhangzhou Hospital Affiliated to Fujian Medical University,Zhangzhou Fujian 363000,China)
出处
《中国卫生标准管理》
2019年第16期65-67,共3页
China Health Standard Management
关键词
鼻咽癌
放射治疗
卡培他滨
化疗
临床表现
安全性
nasopharyngeal carcinoma
radiotherapy
capecitabine
chemotherapy
clinical manifestations
safety
